Section Arrow
QTTB.NASDAQ
- Q32 Bio
Quotes are at least 15-min delayed:2024/12/25 01:38 EST
Last
 3.31
+0.08 (+2.48%)
Day High 
3.34 
Prev. Close
3.23 
1-M High
28.66 
Volume 
229.36K 
Bid
3.15
Ask
3.39
Day Low
3.1501 
Open
3.29 
1-M Low
3.02 
Market Cap 
39.34M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 5.85 
20-SMA 15.55 
50-SMA 32.05 
52-W High 53.79 
52-W Low 3.02 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.05/-5.43
Enterprise Value
51.20M
Balance Sheet
Book Value Per Share
1.50
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
3.21M
Operating Revenue Per Share
0.05
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TNXPTonix Pharmaceuticals Holding Corp.0.3853-0.0178-4.42%-- 
CMNDClearmind Medicine1.72+0.5+40.98%0.16PE
CEROCERo Therapeutics Holdings0.0623+0.0118+23.37%-- 
ATNF180 Life Sciences Corp2.9+1.03+55.08%0.23PE
RXRXRecursion Pharmaceuticals7.24+0.25+3.58%-- 
Quotes are at least 15-min delayed:2024/12/25 01:38 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.